Stock Ratings / Health Care / OMDA / forecast

INNV (57) USPH (64) PNTG (56) TDOC (56) ⌘ Pro Terminal →

Omada Health Inc. (OMDA) 12-Month Stock Forecast & Price Target Cone

$19.65 +2.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Omada Health Inc. (OMDA) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $1.20B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE-0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OMDA)Realized 20D OHLCV Swing Band: ±11.2%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your OMDA Position Size: $10,000

Shares at $19.65: 508.9 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $15.19

$7,730

$-2,270 (-22.7%)

12M Consensus BaseTarget $19.47

$9,908

$-92 (-0.9%)

12M Bull Case BreakoutTarget $27.44

$13,964

+$3,964 (+39.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 6

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$20	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$26	69%	B
JP MorganUS Large-Cap Research	SELL	$17	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OMDA)

✓Walkthrough of OMDA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OMDA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +34.77%📐 HORIZONTAL RANGE

2026-10-30O $19.35H $19.65L $18.47C $19.65VOL 958.6K

RES: $26.98SUP: $17.34SMA50: $20.75SMA200: $17.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OMDA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OMDA Butterfly Map → + Track OMDA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +53.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OMDA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OMDA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OMDA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OMDA)

Health Care Rank #264 of 1016 ⚔️ INNV vs OMDA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OMDA vs. INNV, USPH, PNTG, TDOC)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Omada Health Inc. (OMDA) ranks #264 by composite RQD confidence (56/100, grade D+) and #338 by equity capitalization ($1.20B). Within this direct 5-issuer industry benchmark cohort, USPH leads on earnings valuation at 32.6x trailing P/E, while USPH leads on capital efficiency and profitability with 11.5% ROIC and 19.2% gross margin. USPH currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with OMDA at 56/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OMDA ACTIVE Omada Health Inc.	D+	56/100	—	65.7%	-15.7%	+2.45%	$1.20B	Benchmark Subject
INNV InnovAge Holding Corp.	D+	57/100	—	18.0%	-10.2%	+1.54%	$1.26B	/innv-vs-omda →
USPH U.S. Physical Therapy Inc.	C	64/100	32.6x	19.2%	11.5%	+1.47%	$1.29B	/usph-vs-omda →
PNTG The Pennant Group Inc.	D+	56/100	50.2x	—	11.0%	+0.76%	$1.48B	/pntg-vs-omda →
TDOC Teladoc Health Inc.	D+	56/100	—	—	-17.0%	+26.89%	$1.59B	/tdoc-vs-omda →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001611115

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Omada Health Inc. (OMDA) reported GAAP revenue of $260.2M (+53.2% vs. FY2024 revenue of $169.8M , and +111.9% cumulative change since FY2023) , GAAP net income of -$12.8M, operating cash flow of $18.3M, and free cash flow of $16.9M (+148.7% YoY). On the balance sheet, OMDA closed FY2025 with $305.4M in total assets against $0 in total debt (Altman Z-Score: 8.93, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$260.2M	-$12.8M	$18.3M	$16.9M	$305.4M	—
FY2024 (FY)	2024-12-31	$169.8M	-$47.1M	-$34.2M	-$34.8M	$150.9M	—
FY2023 (FY)	2023-12-31	$122.8M	-$67.5M	-$49.7M	-$49.7M	—	—

3. OMDA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OMDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Omada Health Inc. (NASDAQ: OMDA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $19.65 (+2.45% 1D, market cap $1.20B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, OMDA ranks #264 in composite RQD confidence.

How does OMDA compare to INNV and USPH in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), OMDA carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 65.7%, and ROIC of -15.7%. By comparison, INNV (InnovAge Holding Corp.) holds a D+ grade (57/100 RQD, P/E N/A, ROIC -10.2%, cap $1.26B) and USPH (U.S. Physical Therapy Inc.) posts a C grade (64/100 RQD, P/E 32.6x, ROIC 11.5%, cap $1.29B). Among the 5-stock peer group, USPH leads on earnings multiple (32.6x) while USPH leads on capital efficiency (11.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OMDA?

Per OMDA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001611115), Omada Health Inc. generated $260.2M in revenue (+53.2% YoY), -$12.8M in net income, and $16.9M in free cash flow against $305.4M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OMDA trading relative to its 50-day, 200-day, and 52-week technical levels?

OMDA last traded at $19.65 (+2.45% on volume of 620,107 shares), positioning the stock -5.30% below its 50-day simple moving average ($20.75) and +11.14% above its 200-day simple moving average ($17.68). Across its 52-week range of $10.28 to $26.13, OMDA sits at the 59.1% percentile with a 14-day RSI of 43.6 (NEUTRAL RANGE) and an implied next-earnings move of ±11.2% ($17.45 to $21.85).

OMDA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is OMDA's 12-month stock price target?

Omada Health Inc. (OMDA) carries a 12-month consensus base price target of $19.47 (-0.9% from $19.65), with a bull-case target of $27.44 and a bear-case floor of $15.19.

Is OMDA stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates OMDA D+ (Sell — SELL) with an RQD Confidence score of 56/100.

Direct Sub-Reports: OMDA RQD Cockpit OMDA 12M Forecast OMDA Earnings & Move OMDA Dividends & DRIP OMDA Insiders & 13F OMDA Whale Options OMDA Profit Sankey OMDA News & Why